PATENT CLAIM ANALYSIS

Application Number: 15965638
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-01
Patent Classification: ["514", "125000"]

Abstract:
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Claim (Index 32):
The method according to  claim 29 , wherein the ratio of emulsifier to oil ranges from about 1:1 to 3:1 (wt/wt %).

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.43182
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15012532', '14859013', '15398928', '15705201', '15083071']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7757490365948485
- 35 USC 102 Novelty (BERT): 0.5797875150186512
- Combined Prediction Score: 0.7561528844372288
- Mean Citation Score: 362.065834
- Max Citation Score: 465.3423
- Similarity Product: 403.9908266476572

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test